Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07253181 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours

Study acronym: TREASURE
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria shortened, about 2 wordsv4
  2. Primary endpoint revised
    • Eligibility criteria expanded, about 60 words
    • Secondary endpoints revised (8)
    • Collaborators: 1 to 7
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 2
    • Start date changed from estimate of Dec 30, 2025 to Jan 6, 2026
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Xuanwu Hospital, Beijing
204 trials monitored
See 3 trials at risk
Stroke
3,531 trials monitored
See 153 trials at risk
This study will address the efficacy and safety of Tenecteplase administered in non-endovascular capable center (nECC) in patients with acute ischemic stroke (AIS) caused by anterior circulation large vessel occlusion (acLVO) who present in the 4.5- to 24-hour time window before interhospital transfer to an endovascular capable center (ECC) for endovascular treatment (EVT). * Primary objective: To evaluate the efficacy and safety of Tenecteplase administration at a nECC before EVT transfer compared with standard of care * Secondary objective: To evaluate the impact of time from needle-to-arterial puncture on clinical outcomes Patients who meet inclusion criteria will be randomized to Tenecteplase (0.25mg/kg, maximum 25mg) before transfer or standard of care. A single bolus dose should be injected over 5 seconds.
Trial Details
NCT Number NCT07253181
Lead Sponsor Xuanwu Hospital, Beijing
Collaborators: Boehringer Ingelheim (China) Investment Co., Ltd, Jeffrey Saver, Maarten Lansberg, Thanh N. Nguyen, Pierre Seners, Jens Fiehler, Raul G. Nogueira
Conditions
(from sponsor)		 Acute Ischemic Stroke, Large Vessel Occlusion, Transportation of Patients
Related terms Ischemic Stroke
Enrollment 572 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov